US2002123512A1PendingUtilityA1

Pharmaceutical composition

59
Priority: Jun 20, 1995Filed: Feb 28, 2002Published: Sep 5, 2002
Est. expiryJun 20, 2015(expired)· nominal 20-yr term from priority
Inventors:Hitoshi IkedaTakashi SohdaHiroyuki Odaka
A61P 3/08A61P 5/50A61P 31/10A61P 5/00A61P 43/00A61P 5/48A61K 9/2018A61P 3/10A61K 9/2054A61K 31/52A61K 31/135A61K 31/4439A61K 31/425A61K 31/44A61K 31/50A61K 31/445A61K 31/42A61K 9/4858A61P 3/00A61K 31/64A61K 31/19A61K 31/535A61K 45/06A61K 31/70A61K 31/415A61K 31/4245A61K 31/4427
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with at least one member of the group consisting of an α-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin compound, a squalene synthesis inhibitor, a fibrate compound, a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor.  
     
     
         2 . Pharmaceutical composition according to  claim 1 , wherein the insulin sensitivity enhancer is a compound represented by the formula:  
       
         
           
           
               
               
           
         
       
       wherein R represents an optionally substituted hydrocarbon or heterocyclic group; Y represents a group represented by —CO—, —CH(OH)— or —NR 3 — (wherein R 3  represents an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a C 1-7  divalent aliphatic hydrocarbon group; Q represents oxygen atom or sulfur atom; R 1  represents hydrogen. atom or an alkyl group; ring E may optionally have further 1 to 4 substituents, and the substituents may optionally be combined with R 1  to form a ring; L and M.respectively represent hydrogen atom, or L and M may optionally be combined with each other to form a bond; or a pharmacologically acceptable salt thereof.  
     
     
         3 . Pharmaceutical composition according to  claim 1 , wherein R is an optionally substituted heterocyclic group.  
     
     
         4 . Pharmaceutical composition according to  claim 1 , wherein m is 0.  
     
     
         5 . Pharmaceutical composition according to  claim 1 , wherein X is CH.  
     
     
         6 . Pharmaceutical composition according to  claim 1 , wherein R 1  is hydrogen atom.  
     
     
         7 . Pharmaceutical composition according to  claim 1 , wherein the partial formula:  
       
         
           
           
               
               
           
         
       
       wherein R 2  represents hydrogen atom, an alkyl group, an optionally substituted hydroxyl group, a halogen atom, an optionally substituted acyl group, nitro group or an optionally substituted amino group.  
     
     
         8 . Pharmaceutical composition according to  claim 1 , wherein L and M are hydrogen atom.  
     
     
         9 . Pharmaceutical composition according to  claim 1 , wherein R is pyridyl, oxazolyl or thiazolyl group optionally having 1 to 3 substituents selected from C 1-3  alkyl, furyl, thienyl, phenyl and naphthyl; m is 0; n is 0 or 1; X is CH; A is a bond or —(CH 2 ) 2 —; R 1  is hydrogen atom; the partial formula:  
       
         
           
           
               
               
           
         
       
       and R 2  is hydrogen atom or C 1-4  alkoxy group; and L and M are both hydrogen atom.  
     
     
         10 . Pharmaceutical composition according to  claim 2 , wherein the compound represented by the formula (I) is; pioglitazone.  
     
     
         11 . Pharmaceutical composition according to claim 1, which comprises an insulin sensitivity enhancer in combination with an α-glucosidase inhibitor.  
     
     
         12 . Pharmaceutical composition according to  claim 11 , wherein the α-glucosidase inhibitor is voglibose.  
     
     
         13 . Pharmaceutical composition according to  claim 11 , wherein the insulin sensitivity enhancer is pioglitazone and the α-glucosidase inhibitor is voglibose.  
     
     
         14 . Pharmaceutical composition according to  claim 1 , which is for prophylaxis or treatment of diabetes.  
     
     
         15 . Pharmaceutical composition which comprises a compound represented by the formula:  
       
         
           
           
               
               
           
         
       
       wherein R′ represents an optionally substituted hydrocarbon or heterocyclic group; Y represents a group represented by —CO—, —CH(OH)— or —NR 3 — (wherein R 3  represents an optionally substituted alkyl group); m is 0 or 1; n is 0, 1 or 2; X represents CH or N; A represents a bond or a C 1-7  divalent aliphatic hydrocarbon group; Q represents oxygen atom or sulfur atom; R 1  represents hydrogen atom or an alkyl group; ring E may optionally have further 1 to 4 substituents, and the substituents may optionally be combined with R 1  to form a ring; L and M respectively represent hydrogen atom, or L and M may optionally be combined with each other to form a bond; with a proviso that R′ does not represent benzopyranyl group when m and n are O, X represents CH, A represents a bond, Q represents sulfur atom, R. L and M represent hydrogen atom and ring E does not have further substituents; or a pharmacologically acceptable salt thereof in combination with an insulin secretion enhancer and/or an insulin preparation.  
     
     
         16 . Pharmaceutical composition according to  claim 15 , wherein R′ is an optionally substituted heterocyclic group.  
     
     
         17 . Pharmaceutical composition according to  claim 15 , wherein m is 0.  
     
     
         18 . Pharmaceutical composition according to  claim 15 , wherein X is CH.  
     
     
         19 . Pharmaceutical composition according to  claim 15 , wherein R 1  is hydrogen atom.  
     
     
         20 . Pharmaceutical composition according to  claim 15 , wherein the partial formula:  
       
         
           
           
               
               
           
         
       
       wherein R 2  represents hydrogen atom, an alkyl group, an optionally substituted hydroxyl group, a halogen atom, an optionally substituted acyl group, nitro group or an optionally.substituted amino group.  
     
     
         21 . Pharmaceutical composition according to  claim 15 , wherein L and M are hydrogen atom.  
     
     
         22 . Pharmaceutical composition according to  claim 15 , wherein R′ is pyridyl, oxazolyl or thiazolyl group optionally having 1 to 3 substituents selected from C 1-3  alkyl, furyl, thienyl, phenyl and naphthyl; m is 0; n is 0 or 1; X is CH; A is a bond or —(CH 2 ) 2 —; R 1  is hydrogen atom; the partial formula:  
       
         
           
           
               
               
           
         
       
       and R 2  is hydrogen atom or C 1-4  alkoxy group; and L and M are both hydrogen atom.  
     
     
         23 . Pharmaceutical composition according to  claim 15 , wherein the compound represented by the formula (II) is the compound represented by the formula:  
       
         
           
           
               
               
           
         
       
     
     
         24 . Pharmaceutical composition according to  claim 15 , wherein the compound represented by the formula (II) is pioglitazone.  
     
     
         25 . Pharmaceutical composition according to  claim 15 , wherein the insulin secretion enhancer is glibenclamide.  
     
     
         26 . Pharmaceutical composition according to  claim 15 , wherein the compound represented by the formula (II) is pioglitazone and the insulin secretion enhancer is glibenclamide.  
     
     
         27 . Pharmaceutical composition according to  claim 15 , which is for prophylaxis or treatment of diabetes.  
     
     
         28 . Method for treating diabetes in a mammal in need thereof, which comprises administering such mammal a therapeutically effective amount of a pharmaceutical composition as defined in  claim 1 .  
     
     
         29 . Method for treating diabetes in a mammal in need thereof, which comprises administering such mammal a therapeutically effective amount of a pharmaceutical composition as defined in claim  15 .

Join the waitlist — get patent alerts

Track US2002123512A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.